glp 1 and chronic kidney disease GLP-1 the kidney: from physiology to pharmacology and outcomes in diabetes SGLT2 vs GLP-1 for CKD:

For Overweight/Obese Patients: Individuals prescribed Wegovy for weight management saw an even more dramatic spike, measuring 7 times more likely to develop NAION than those using alternative weight-loss treatments

Switching from semaglutide to tirzepatide Switching from Ozempic to Mounjaro or Wegovy to Zepbound is possible when done under the guidance of a healthcare provider

My digestion improved, and the feeling of fullness lasted longer

Discontinuing GLP-1 medicines frequently results in a weight increase even if the person follows a healthy diet and lifestyle

That said, these effects are not yet well established clinically, and more research is needed to determine whether they are directly caused by the medication or influenced by factors such as weight loss, metabolic changes, or individual physiology

The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions